Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

Trial Details

NCT ID
NCT03681561
Phase
PHASE1 / PHASE2
Sponsor
Veronika Bachanova
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Ruxolitinib
  • Nivolumab
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the infor…
  • Age ≥ 18 years at the time of consent.
  • ECOG Performance Status of 0, 1 or 2.
  • Histologically confirmed diagnosis of classical Hodgkin lymphoma that is relapsed or refractory - historical biopsy at last relapse is acceptable. …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →